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Sacubitril/valsartan is superior to enalapril in reducing the risks of cardiovascular death and preventing 
hospitalization in patients with heart failure and reduced ejection fraction (HFrEF). However, patients 
often do not receive sacubitril/valsartan because of concerns about hypotension. We examined the 
feasibility of initiating sacubitril/valsartan at a very low dose (VLD) in potentially intolerant patients 
with HFrEF and subsequent dose up‑titration, treatment persistence and outcomes. We analyzed 
206 patients with HFrEF grouped according to starting sacubitril/valsartan dose. The VLD group 
(n = 106) commenced 25 mg twice daily, and the standard‑dose (SD) group (n = 100) started on ≥ 50 mg 
twice daily. Baseline systolic blood pressure was 103 ± 12 mmHg vs. 119 ± 14 mmHg in the SD group 
(P < 0.001). The maximal target dose achievement rate was higher in the SD group (27.0% vs 9.4%, 
p = 0.001) and the VLD group experienced more dose up‑titrations and fewer down‑titrations than 
the SD group. The VLD group had a decrease in N‑terminal prohormone of brain natriuretic peptide 
(NT‑proBNP) similar to the SD group and a similar increase in left ventricular ejection fraction. There 
were no significant differences in symptomatic hypotension, worsening renal function, hyperkalemia, 
cardiovascular mortality, and rehospitalization due to HF between the two groups during follow‑up 
period. In patients considered by the treating physician likely to be intolerant of sacubitril/valsartan, 
initiation with 25 mg twice daily was generally possible and patients remained in therapy, with similar 
decreases in NT‑proBNP and increases in left ventricular ejection fraction to those observed in patients 
receiving SD sacubitril/valsartan.
In the PARADIGM-HF [Prospective Comparison of Angiotensin Receptor/Neprilysin Inhibitor (ARNI) Sacu-
bitril/Valsartan (SV) with Angiotensin-converting Enzyme Inhibitor (ACEi) to Determine Impact on Global 
Mortality and Morbidity in Heart Failure (HF) trial], SV (LCZ696) significantly reduced cardiovascular (CV) 
mortality and HF hospitalization, compared to enalapril in patients with HF with reduced ejection fraction 
(HFrEF)1. Based on this result, current guidelines give a Class I recommendation for the use of SV in patients 
with  HFrEF2,3. Despite the current guideline recommendations, the prescription rate of SV remains still low in 
“real-world” clinical  practice4–8. In PARADIGM-HF, the pre-SV treatment dose of enalapril during run-in was 
10 mg twice daily. However, patients in clinical practice may not be tolerant of this relatively high dose of an 
ACEi or equivalent dose of angiotensin receptor blocker (ARB). Recent studies showed that sub-optimal ACEi 
or ARB dosing may be one of the main reason for non-use of  SV9,10. Moreover, when SV has been prescribed, 
it has often been at a lower dose 50–100 (24/26–49/51) mg twice daily, and physicians report that SV users are 
often unable to reach the maximal target dose 200 (97/103) mg twice daily because of  intolerance4–8. Real-world 
data show that the maximal target dose achievement rate for SV is only 27 to 38%4,6. There have been no studies 
(including the PARALLEL-HF trial conducted in Japan) examining the initiation of SV at a very low dose, such 
as 25 (12/13) mg twice daily in ambulatory patients, or which have compared this to the standard dose (SD) of 
50 (24/26) mg twice  daily11. In the present study, we examined the tolerability of SV commenced at a very low 
dose (VLD), and outcomes associated with this dose, compared to SD SV in patients with HFrEF.
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Methods
Study population. This study was a single-center, prospective, observational study conducted at a tertiary 
university  hospital12,13. The consecutive outpatients (≥ 18 years old) enrolled in this study from Jan 2017 to Sep 
2018 had the following characteristics: (1) symptomatic chronic HF with New York Heart Association (NYHA) 
class II–IV, (2) left ventricular ejection fraction (LVEF) ≤ 40% in echocardiography, (3) use of a maximally tol-
erated dose of an ACEi/ARB for at least 4  weeks, and (4) use of other guideline-directed medical therapies 
(GDMT) for HF such as beta-blockers, mineralocorticoid receptor antagonists (MRA) or ivabradine, unless 
there were contraindications to these  treatments14.
Data collection. We reviewed medical records including laboratory data, medical history, pre-SV prescrip-
tion therapy, and echocardiographic parameters at baseline. Patients were followed up every 1 to 6  months, 
and blood samples collected and physical examination, including measurement of office blood pressure (BP), 
performed at each visit. Echocardiographic parameters were assessed at least 12 weeks after SV treatment. Drug 
administration doses, including SV, beta-blocker, MRA and loop diuretics, were collected at the initial and fol-
low-up visits. Only patients with a titration period of at least 6 months after starting SV were included. Com-
posite clinical outcomes consisted of cardiovascular mortality and rehospitalization due to HF. This study was 
approved by the institutional review board of the Yonsei University Health System (2020-0401-001).
Sacubitril/valsartan doses and titration patterns. Patients were stratified according to the dose of 
SV as follows; patients in the ‘VLD’ group received a dose of SV 25 mg twice daily and those in the ‘SD’ group 
received more than 50 mg or more twice daily, at the beginning of the study. VLD SV was prepared by the local 
pharmacy. The physician decision about which SV dose to start with was based on prior ACEi/ARB dose and 
BP. The pre-SV treatment dose of an ACEi/ARB were classified into two categories; a high-dose ACEi/ARB 
group defined as a total daily dose of enalapril > 10 mg or valsartan > 160 mg, or equivalent, and low-dose group, 
defined as a lower dose than the high-dose group. Patients on another ACEi/ARB had their dose adjusted to 
an equivalent dose of valsartan as done in the TITRATION  trial15. Doses of beta-blockers were calculated as 
carvedilol  equivalents16, and loop-diuretic dosing was calculated as furosemide  equivalents17. Dose titration 
was considered in five categories; (1) maintenance, (2) dose-up, (3) dose-down, (4) dose-up & down and (5) 
 discontinuation15.
Tolerability according to adverse events and clinical outcomes. Tolerability was defined as 
the presence or absence of events including symptomatic hypotension (symptoms and systolic blood pres-
sure, SBP < 100  mmHg at follow-up visit), worsening renal function (estimated glomerular filtration rate, 
eGFR < 30 mL/min/1.73  m2) and hyperkalemia (serum potassium > 5.5 mmol/L). The proportion of patients that 
achieved the maximal target dose without adverse events (or death) were assessed. The main clinical outcome 
was the composite of cardiovascular mortality or HF rehospitalization.
Statistical analysis. Continuous quantitative variables were presented as mean ± standard deviation, and 
categorical data were presented as frequencies and percentages. We analyzed the differences between groups 
using the χ2 test or Fischer’s exact test for categorical variables and student’s t test or Wilcoxon rank sum for 
continuous variables. Time-to-event data for comparing the clinical outcomes between two groups were ana-
lyzed with the Kaplan–Meier curve and log-rank test. P-values < 0.05 represented statistically significant results. 
We performed all the analyses with SPSS version 25.0 statistical package (SPSS Inc., an IBM company, Chicago, 
IL, USA).
Declaration of Helsinki. This study was approved by the Institutional Review Board of Severance Hos-
pital (IRB no. 2020-0401-001) and conformed to the ethical guidelines from the 1975 Declaration of Helsinki. 
Informed consent was obtained from all subject and/or real guardian.
Results
Baseline characteristics. We analyzed 206 patients with HFrEF (mean age 63 ± 14 years, EF 26.4 ± 6.1%) 
that were treated with SV from January 2017 to Sep 2018 consecutively (median follow-up duration 285 days). 
Table 1 show the baseline clinical characteristics, including medical history, laboratory parameters and pre-SV 
treatment medications. Compared to patients in the SD group (n = 100), those commenced on the VLD (n = 106) 
of SV had a lower body mass index (BMI), lower SBP, lower LVEF and they were less likely to have a history of 
hypertension and diabetes mellitus. A higher proportion of patients in the VLD group had a SBP < 100 mmHg at 
the time of switching from an ACEi/ARB to SV.
Dosing of sacubitril/valsartan. We analyzed baseline SBP and the pre-SV ACEi/ARB dose in relation to 
initial dose of SV (supplementary table 1). Patients with both a high SBP and a high ACEi/ARB dose were more 
likely to be prescribed SD SV (39% vs. 9.4%, p < 0.001) and patients with both a low SBP and a low ACEi/ARB 
dose were more likely to be commenced on VLD SV (34% vs. 5%, p < 0.001). Detailed descriptions about the 
medication types and dosing of pre-SV HF-GDMT are summarized in supplementary Table 2. In the SD group, 
equivalent valsartan and carvedilol doses were significantly higher compared to the VLD group.
Change in physiological measures and clinical outcomes after initiation of sacubitril/valsar‑
tan. Table 2 shows changes in laboratory and echocardiographic parameters after initiating SV treatment. 
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Follow-up SBP was lower and follow-up NT-proBNP level was higher in the VLD group when compared to the 
SD group, reflecting differences in these variables observed at baseline.
In the overall population, SBP did not show a significant change from baseline to follow-up (from 111 ± 15 
to 110 ± 17 mmHg, p = 0.751). However, after treatment with SV, SBP increased in the VLD group and decreased 
in the SD group, with a significant difference between the two groups (p = 0.014). In the overall population, NT-
proBNP decreased following treatment with SV (from 2594 ± 4168 to 2199 ± 6253 pg/ml, p < 0.001), left ventricu-
lar end-diastolic dimension (LVEDD) decreased (from 65 ± 8 to 61 ± 9 mm, p < 0.001) and LVEF increased (from 
26.4 ± 6.2 to 35.7 ± 12.0%, p < 0.001). The changes in NT-proBNP, LVEDD, and LVEF did not differ significant 
between the two dose-groups. Symptoms (NYHA classification) also improved after SV treatment (supplementary 
table 3). During the follow-up period, there were 27 composite clinical outcomes including 4 CV deaths and 23 
HF rehospitalizations, with no significant difference between the two dose-groups (Fig. 1).
Table 1.  Baseline characteristics. SBP systolic blood pressure, NYHA New York Heart Association, LVEF left 
ventricular ejection fraction, eGFR estimated glomerular filtration rate, NT-proBNP N-terminal prohormone 
of brain natriuretic peptide, SV sacubitril/valsartan.
Variables
Very low-dose Standard dose
p value(N = 106) (N = 100)
Male, n (%) 73 (68.9%) 72 (72.0%) 0.623
Age (years) 61.7 ± 15.2 63.5 ± 13.4 0.363
Body mass index (kg/m2) 23.5 ± 3.5 25.6 ± 4.1  < 0.001
Etiology 0.843
Ischemic cardiomyopathy, n (%) 31 (29.2%) 28 (28.0%)
Non-ischemic cardiomyopathy, n (%) 75 (70.8%) 72 (72.0%)
SBP (mm Hg) 102.8 ± 12.0 118.7 ± 13.8  < 0.001
SBP < 100 mmHg, n (%) 40 (37.7%) 6 (6.0%)  < 0.001
Heart rate (/min) 73.0 ± 14.6 71.6 ± 12.7 0.451
NYHA classification, n (%) 0.930
II 95 (89.6%) 90 (90.0%)
III 11 (10.4%) 10 (10.0%)
Medical history, n (%)
Hypertension 55 (51.9%) 74 (74%) 0.001
Diabetes 23 (21.7%) 36 (36%) 0.022
Dyslipidemia 13 (12.3%) 19 (19.0%) 0.172
Myocardial infarction 20 (18.9%) 23 (23.0%) 0.443
Stroke 11 (10.4%) 9 (9.0%) 0.756
Atrial fibrillation 35 (33.0%) 32 (32.0%) 0.915
Chronic kidney disease 41 (38.7%) 37 (37.0%) 0.847
Laboratory parameter
Blood urea nitrogen (mg/dL) 21.8 ± 10.6 22 ± 9.8 0.910
Creatinine (mg/dL) 1.1 ± 0.4 1.1 ± 0.4 0.854
eGFR (mL/min/1.73m2) 67.2 ± 19.9 66.2 ± 19.2 0.716
Sodium (mmol/L) 140.2 ± 2.6 140.9 ± 2.7 0.101
Potassium (mmol/L) 4.6 ± 0.5 4.6 ± 0.5 0.847
Hemoglobin (g/dL) 13.4 ± 1.8 13.8 ± 2.1 0.171
NT-proBNP (pg/mL) 2750.9 ± 4453.6 2311.1 ± 3662.1 0.475
Echocardiograhic parameter
LVEF (%) 25.4 ± 6.1 27.3 ± 5.9 0.026
LVEDD (mm) 65.5 ± 9.4 64.7 ± 7.0 0.447
Pre-SV treatment therapy
Angiotensin-converting enzyme inhibitor, n (%) 11 (10.4%) 13 (13.0%) 0.558
Angiotensin II receptor blocker, n (%) 95 (89.6%) 87 (87.0%) 0.558
Beta-blocker, n (%) 96 (90.6%) 93 (93.0%) 0.526
Mineralocorticoid receptor antagonist, n (%) 85 (80.2%) 75 (75.0%) 0.371
Loop diuretics, n (%) 89 (84%) 83 (83.0%) 0.852
Ivabradine, n (%) 21 (19.8%) 12 (12.0%) 0.127
Implantable cardioverter defibrillator, n (%) 40 (37.7%) 35 (35.0%) 0.723
Cardiac resynchronization therapy, n (%) 11 (10.4%) 15 (15.0%) 0.305
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Dose titration, the achievement of maximal target dose and adverse events. As shown in 
Fig. 2A, we found that the VLD group had more up-titrations (45.3% vs. 32.0%, p = 0.051), while patients in the 
SD group had more down-titrations (21.0% vs. 4.7%, p < 0.001). Discontinuation rates of SV were comparable 
between the two groups. Specifically, 6/106 patients (5.7%) in the VLD group and 7/100 patients (7.0%) in 
the SD group stopped SV for reasons other than death (P = 0.693). Table 3 shows the titration tolerability and 
adverse events during treatment with SV. Achievement of the maximal target dose of SV was higher in the SD 
group (Fig. 2B). The most common cause for intolerance during up-titration was dizziness, and more patients 
Table 2.  Changes in laboratory and echocardiographic parameters after treatment with sacubitril/valsartan. 
SBP systolic blood pressure, DBP diastolic blood pressure, NT-proBNP N-terminal prohormone of brain 
natriuretic peptide, LVEDD left ventricular end diastolic diameter, LVEF left ventricular ejection fraction.
Variables
Very low-dose Standard dose
p value(N = 106) (N = 100)
SBP (mmHg)
Baseline 102.8 ± 12.0 118.7 ± 13.8  < 0.001
Follow-up 105.2 ± 16.0 115.3 ± 16.2  < 0.001
∆ Delta 2.4 ± 15.5 − 3.4 ± 17.8 0.014
DBP (mmHg)
Baseline 65.2 ± 10.0 73.6 ± 12.2  < 0.001
Follow-up 64.9 ± 10.7 70.2 ± 13.1 0.002
∆ Delta − 0.3 ± 11.1 − 3.4 ± 17.0 0.133
Log NT-proBNP
Baseline 3.1 ± 0.6 3.0 ± 0.6 0.257
Follow-up 2.8 ± 0.7 2.5 ± 0.8 0.030
∆ Delta − 0.3 ± 0.6 − 0.4 ± 0.6 0.096
LVEDD (mm)
Baseline 65.5 ± 9.4 64.7 ± 7.0 0.447
FOLLOW-up 61.8 ± 9.7 59.8 ± 7.6 0.140
∆ Delta − 3.8 ± 5.7 − 4.5 ± 6.3 0.420
LVEF (%)
Baseline 25.4 ± 6.1 27.3 ± 5.9 0.026
Follow-up 34.2 ± 12.5 37.3 ± 11.2 0.081
∆ Delta 9.0 ± 12.3 9.9 ± 12 0.610
Figure 1.  Kaplan–Meier curve for clinical outcomes between very low-dose sacubitril/valsartan and 
standard dose group. Event-free survival of the composite-end point (cardiovascular death or heart failure 
rehospitalization) (Panel A) and heart failure (HF) rehospitalization (Panel B).
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Figure 2.  Heart failure guideline-directed medical therapies at follow-up compared with baseline for very 
low-dose and standard dose of sacubitril/valsartan groups. Panel (A) Pattern of dose titration, comparing very 
low-dose and standard dose sacubitril/valsartan groups (panel A). Pane (B) Proportions of patients achieving 
different sacubitril/valsartan dose levels in the very low-dose and standard dose sacubitril/valsartan groups 
(panel B). Panel C: Dosing of other heart failure treatments in the very low-dose and standard dose sacubitril/
valsartan groups. The p-value represents a comparison between very low-dose and standard dose of sacubitril/
valsartan at baseline and follow-up.
Table 3.  The achievement rate of the maximal target dose of sacubitril/valsartan, tolerability, and adverse 
events. SBP systolic blood pressure, eGFR estimated glomerular filtration rate.
Very low dose Standard dose
p value(N = 106) (N = 100)
Mean dose on last follow-up (mg) 115.0 ± 108.2 210.8 ± 137.6 0.001
Achieving maximal target dose (200 mg twice daily), n (%) 10 (9.4%) 27 (27.0%) 0.001
Causes of titration intolerance, n (%) 0.049
Dizziness 12 (11.3%) 24 (24.0%)
Decreased SBP 7 (6.6%) 6 (6.0%)
General weakness 0 (0%) 1 (1.0%)
Decreased renal function 1 (0.9%) 2 (2.0%)
Others 2 (1.9%) 5 (5.0%)
Adverse events, n (%)
Hypotension (SBP < 100 mmHg) 23 (21.7%) 16 (16.0%) 0.297
Symptomatic hypotension (SBP < 100 mmHg) 7 (7.0%) 3 (2.8%) 0.204
Decreased renal function
(eGFR < 30 mL/min/1.73m2) 6 (5.7%) 3 (3.0%) 0.402
Hyperkalemia (K > 5.5 mg/dL) 6 (5.7%) 4 (4.0%) 0.752
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complained of dizziness in the SD group compared to the VLD group. The most common adverse event was 
hypotension, but there was no significant difference in the adverse events between the two dose-groups.
We analyzed the prescription rate and equivalent dose of other GDMT medications for heart failure before 
and after treatment with SV (Fig. 2C, supplementary table 4). In the SD group, beta-blockers were used at 
higher doses at both baseline (12.9 ± 9.7, vs 9.0 ± 5.2 mg p = 0.001) and follow-up (15.6 ± 14.8 vs. 10.2 ± 7.9 mg, 
p = 0.003), compared to the VLD group. However, there were no significant differences in prescription rates and 
dose changes of beta-blockers during follow-up (or for MRA and loop diuretics).
Discussion
In the present study, we demonstrated that patients with HFrEF initiated on a VLD of SV were characterized 
by lower SBP, BMI, and LVEF at baseline. Use of VLD SV was associated with an improvement in dyspnea, an 
increase in LVEF and a decrease in NT-proBNP and LVEDD, similar to that seen with the currently recom-
mended SD of SV, and without any significant differences in adverse events, treatment discontinuation or clinical 
outcomes, when compared with SD of SV.
Based on the clinical benefits demonstrated in the PARADIGM-HF trial, both the ACC/AHA and ESC guide-
lines recommend SV treatment in patients with  HFrEF2,3. However, according to a recent report about GDMT in 
HFrEF (CHAMP-HF, Change and Management of Patients with Heart Failure), 27% of patients did not receive an 
ACEi/ARB or SV despite absence of contraindications and only 13% of patients received  SV8. Another analysis 
of the CHAMP-HF registry showed that only 10.8% patients took the target dose of ACEi/ARB, recommended 
by current  guidelines18. These results suggest that initiation and up-titration of GDMT to target doses is often a 
clinical challenge in ordinary clinical practice.
The greatest challenge is in patients with a low BP (e.g. SBP < 100 mmHg) who are also those at highest risk 
of poor outcomes and who, potentially, have much to gain from effective therapies. A post-hoc analysis of the 
Systolic Heart Failure Treatment with the  If Inhibitors Ivabradine (SHIFT) showed that the risk of all-cause 
mortality increased by 12% as baseline SBP decreased every 10 mmHg in chronic HFrEF  patients19. The signifi-
cance of low BP is further highlighted by the definition of “advanced heart failure” which includes patients with 
a SBP < 90 mmHg, and in whom treatments such as a left ventricular assist device or even heart transplantation 
may need to be  considered3,20. In the real-world practice, it is easy to find patients with HFrEF with a low SBP, as 
shown in our study. Interestingly, in this study, the patients that physicians elected to start on VLD SV had other 
features of advanced heart failure. For example, they had a lower BMI which is known to identify higher-risk 
individuals, some of whom have cardiac cachexia, which is also part of the definition of advanced heart  failure21. 
Finally, they had a lower LVEF (LVEF < 30%) and this too is also a recognized indicator of advanced  HF20.
These high-risk HF patients have a poor tolerance of GDMT, and so it is inevitable that lower doses of 
guideline-recommended medications are prescribed in clinical practice (or these may not be prescribed at all). 
However, there have been few clinical studies that have examined the possibility of using lower than usual initial 
doses of GDMT in patients with HFrEF. We found that a VLD of SV was associated with similar improvements 
in symptoms, laboratory, echocardiographic parameters, and clinical outcomes, and had a similar adverse event 
profile in these vulnerable patients, compared to the SD group. Although our patients were not randomized, it is 
useful to compare our results with those from the PIONEER-HF trial in which hospitalized HFrEF patients with 
a systolic BP ≥ 100 mmHg were randomized to SV 50 mg bid (titrated, if possible, to 200 mg bid) or enalapril 
2.5 mg bid (titrated to 10 mg bid)22. In PIONEER-HF, the lowest dose-level of SV (50 mg bid) led to a greater 
reduction in NT-proBNP than the equivalent randomized dose-level of enalapril (2.5 mg bid). Compared with 
enalapril, SV also reduced heart failure re-hospitalization, consistently, across all three dose-levels of study 
drug (50, 100 and 200 mg bid of SV versus 2.5, 5 and 10 mg bid of enalapril). While we cannot prove that those 
individuals who remained on VLD SV (i.e. 25 mg bid) obtained benefit from that dose, we can conclude from 
PIONEER-HF that the 49% who were successfully titrated to 50 mg bid or above likely did. It is also important 
to note that 94% of patients in the VLD group remained on SV. In the SD group, 78% of patients achieved a dose 
of SV of 50 mg bid or above and 93% remained on treatment. For comparison, 88% of patients in PIONEER-HF 
remained on SV of 50 mg bid or above at 12 weeks but 12% were off study drug (there was no 25 mg bid option 
in PIONEER-HF). Arguably, the availability of VLD SV resulted on more patients remaining on treatment in 
the present study and possibly some patients receiving treatment at all i.e. if it had not been for the availability of 
VLD SV, some patients might never have been started on treatment or would have been started on SD and had to 
discontinue treatment. Conversely, a forced-titration strategy, such as that used in randomized trials, might have 
led to achievement of higher doses that observed in our study, although other “real world” data are consistent 
with our experience, e.g. in the CHAMP-HF Registry, only 14% of patients received maximal target doses of  SV8.
Our findings may be particularly relevant to Asian patients. In the PARADIGM-HF trial, the 1487 (18%) 
patients enrolled from the Asia–Pacific region had a lower BMI, lower SBP and lower prevalence of hypertension, 
findings comparable with our baseline  data23,24. Clinical practice data from Taiwan demonstrated that only 15.8% 
patients could achieve the target SV dose (97/103 mg twice daily) after a 1-year titration  pattern25. In addition, 
this study showed that very low doses of SV (12/13 to 24/26 mg daily) were prescribed. Therefore, future prospec-
tive studies to demonstrate the clinical role of a very low SV dose should be warranted, especially in the Asian 
population. However, it is important to reach the maximal target dose (200 mg twice daily) because the patients 
taking the full dose sacubitril/valsartan showed lower cardiovascular death or heart failure hospitalization then 
those taking lower than target doses of  enalapril26. Following current guidelines, the clinician should strive to 
reach the maximal target dose as soon as possible.
Our study had some limitations. First, it had the inherent limitations of an observational study in a single 
center. Second, we used a very low dose of SV that is not generally available and had to be prepared locally 
by splitting a 50 mg SV tablet. Third, we analyzed a relatively small number of patients in a specific (Korean) 
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population with a relatively short-term follow-up. A larger prospective, larger, longer term, randomized trial 
would be useful.
In conclusion, our study suggests that the initiation of VLD of SV (25 mg twice daily), in patients taking 
a low dose of an ACEi/ARBs, or with a low SBP, or both, is well tolerated and may be associated with similar 
outcomes an initial standard dose of 50 mg twice daily. This may be a useful clinical strategy in the many HFrEF 
patients who are currently denied SV and other therapies because of concerns about hypotension or who are 
unable to tolerate standard dose SV. Therefore, more attention should be warranted to our new strategy in a 
real practice, and individualized target dose for sacubitril/valsartan should be set based on SBP, body weight or 
severity of HF patients.
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